Home › Non-Small Cell Lung Cancer › Texas
Non-Small Cell Lung Cancer clinical trials in Texas
204 studies for Non-Small Cell Lung Cancer are looking for participants at sites in Texas.
Cities in Texas
- Houston145 studies
- San Antonio59 studies
- Dallas52 studies
- Austin30 studies
- Irving23 studies
- Tyler20 studies
- Fort Worth18 studies
- The Woodlands15 studies
- League City15 studies
- Abilene8 studies
- Sugar Land8 studies
- Amarillo8 studies
- El Paso6 studies
- Plano5 studies
- Killeen4 studies
- Round Rock4 studies
- Waco4 studies
- Denton4 studies
- Odessa4 studies
- Arlington4 studies
- Lubbock4 studies
- Denison3 studies
- Wichita Falls3 studies
- Longview3 studies
- Pearland3 studies
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Texas Oncology - DFW ( Site 8103), Dallas
- UT Southwestern Medical Center ( Site 0190), Dallas
- Houston Methodist Cancer Center ( Site 0191), Houston
- and 5 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06623422A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Texas Oncology - West Texas, Abilene
- Texas Oncology-Northeast Texas, Allen
- Texas Oncology-West Texas, Amarillo
- and 61 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07144280Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Hendrick Medical Center, Abilene
- Houston Methodist San Jacinto Hospital, Baytown
- Parkland Memorial Hospital, Dallas
- and 6 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT04267848A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
- University of Texas Medical Branch, Galveston
- The University of Texas MD Anderson Cancer Center, Houston
- Baylor Scott & White Health, Temple
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07154290Dyadic Yoga Program for Patients Undergoing Thoracic Radiotherapy and Their Family Caregivers: The Testing of a Mobile Application Delivery
- The University of Texas M. D. Anderson Cancer Center, Houston
Recruiting
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06919874A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Oncology Consultants PA, Houston
- University of Texas MD Anderson Cancer Center, Houston
- US Oncology Research Investigational Products Center, Irving
RecruitingPhase 3
Ages 18 to 100 · All sexes · Updated Sep 25, 2026 · NCT05920356Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer
- UT MD Anderson, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07579221A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
- Research Site, Round Rock
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06868277Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Texas Oncology - West Texas, Abilene
- Texas Oncology - Northeast Texas, Allen
- Texas Oncology - West Texas, Amarillo
- and 52 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07222566A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06172478A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
- MD Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06667908This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- The University of Texas, MD Anderson Cancer Center - Woodlands, Conroe
- Renovatio Clinical - El Paso, El Paso
- The University of Texas MD Anderson Cancer Center Diagnostic Imaging, Houston
- and 10 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06758401Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
- Research Site, Dallas
- Research Site, Galveston
- Research Site, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06218914A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Texas Oncology South, Austin
- Parkland Health and Hospital System, Dallas
- Texas Oncology DFW, Dallas
- and 8 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06667076A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
- START Fort Worth, Fort Worth
- MD Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07659782Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
- Dallas Cancer Specialists, Garland
- Southwest Oncology Associates, Houston
- Lumi Research, Houston
- and 2 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07227298Pan-tumor MRD Study
- Onocology Consultants P.A. (Oncology Consultants [OC Houston]), Houston
- Community Clinical Trials, Kingwood
- Christus St. Michael's, Texarkana
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06605404Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Baylor, Scott and White Research Institute, Dallas
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06047379Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- The Center for Cancer and Blood Disorders, Fort Worth
- Kelsey-Seybold Clinic, Houston
- Houston Methodist Hospital, Houston
- and 4 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06890598A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Texas Oncology - West Texas, Abilene
- University of Texas MD Anderson Cancer Center, Houston
- Local Institution - 0517, Houston
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06561386A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
- UT Southwestern Medical Center at Dallas, Dallas
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07140016Intratumoral N17350 in Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07339176Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- Research Site, Houston
RecruitingPhase 2
Ages 18 to 95 · All sexes · Updated Sep 23, 2026 · NCT05061550Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Research Site, Fort Worth
- Research Site, Houston
- Research Site, Kingwood
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06357533A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- NEXT Oncology - Irving, Irving
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06618287An External Control Arm Study in Non-Small Cell Lung Cancer
- Oncology Consultants, Houston
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07174388Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
- Joe Arrington Cancer Research /ID# 272776, Lubbock
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06772623A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Texas Oncology Sammons Cancer Center, Dallas
- Local Institution - 0692, Galveston
- Local Institution - 0652, Laredo
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06875310Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Local Institution - 0025, Houston
- Local Institution - 0173, San Antonio
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07100080Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer
- Oncology Consultants, P.A., Houston
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07028489A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Texas Oncology - Dallas - Worth Street /ID# 278947, Dallas
- Texas Oncology - Northeast Texas /ID# 272000, Tyler
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06568939A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
- Next Oncology - Austin, Austin
- Next Oncology - Houston, Houston
- Next Oncology - Dallas, Irving
- and 1 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07488676Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- MD Anderson, Houston
- NEXT Dallas, Irving
- NEXT Oncology San Antonio, San Antonio
- and 1 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06128551A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT07629960Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Oncology Consultants, P.A., Houston
- University of Texas M.D. Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05983432Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- Texas Oncology (Balcones) - SCRI, Austin
- MD Anderson Cancer Center, Houston
- START South Texas Accelerated Research Therapeutics, San Antonio
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT05267626A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Research Site, Fort Worth
- Research Site, Kingwood
- Research Site, Lubbock
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT06692738Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Clinical Study Site, Abilene
- Clinical Study Site, Austin
- Clinical Study Site, Dallas
- and 4 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT06767514A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
- NEXT Oncology, San Antonio
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT07705334A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
- MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07020117From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.